NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 23 2025
0mins
Source: PRnewswire
Merger Announcement: NLS Pharmaceutics Ltd. and Kadimastem Ltd. have announced an update regarding their proposed merger, aimed at enhancing their capabilities in treating CNS disorders and neurodegenerative diseases.
Company Profiles: NLS Pharmaceutics is a Swiss clinical-stage biopharmaceutical company, while Kadimastem is an advanced clinical-stage cell therapy company focused on neurodegenerative diseases and diabetes.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
